Microvascular Obstruction has very quietly become one of the most relevant and hotly debated topics in Interventional Cardiology. Some technologies are being developed to diagnose this disease, and others to treat it. CorFlow’s CoFi system has been designed to do both. Paul Mead (CEO of CorFlow) sits down with Mike Moore to discuss this bold and exciting endeavor.
Having successfully completed the first-in-human MOCA-I trial in 2024, the MOCA-II study is the next critical step to bringing this unique technology into the hands of interventional cardiologists globally for the rapid diagnosis of MVO in heart attack patients. Read More:
We are absolutely thrilled to announce that Chris O’Connell has joined CorFlow as Chairman of the Board. Chris brings a huge amount of experience and we are delighted that he is joining the team!
We are excited to share that we have completed a €44 million Series B financing to move our clinical programme to the next phase. Building on the First in Human MOCA I trial, we are committed to delivering the international pivotal trial in parallel with a randomized trial to evaluate therapies to treat MVO through our CoFi system.
We are delighted to share that, alongside our partners BYTEC Medizintechnik GmbH, the next generation CorFlow Infusion System was demonstrated at the Compamed exhibition. BYTEC has been developing and manufacturing high-tech medical devices in diagnostics, surgery and therapy for more than 30 years.
The system created a lot of interest from delegates from within Europe as well as from further afield. For further information please contact us!
At the end of August 2023, the European Society of Cardiology released the new guidelines on the management of acute coronary syndromes, combining for the first time the previous STEMI and ACS guidelines. Of note, the experts stated:
“Microvascular obstruction associated with pPCI represents an unmet clinical need in patients with ACS. Development of therapies for the prevention and treatment of MVO is urgently needed.”